Oral live attenuated human rotavirus vaccine (RotarixTM) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children
In a large Phase III trial conducted in 10 Latin American countries, the safety and efficacy of the live attenuated monovalent rotavirus vaccine RIX4414 was evaluated in 15,183 healthy infants followed up during the first two years of life. Belém was the only site in Brazil included in this multicen...
| Autor principal: | JUSTINO, Maria Cleonice Aguiar |
|---|---|
| Outros Autores: | ARAÚJO, Eliete da Cunha, VAN DOORN, Leen-Jan, OLIVEIRA, Consuelo Silva de, GABBAY, Yvone Benchimol, MASCARENHAS, Joana D'Arc Pereira, MIRANDA, Yllen Stefania Affonso, GUERRA, Sylvia de Fátima dos Santos, SILVA, Veronilce Borges da, LINHARES, Alexandre da Costa |
| Grau: | Artigo |
| Idioma: | eng |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: |
http://repositorio.ufpa.br/jspui/handle/2011/7002 |
| id |
ir-2011-7002 |
|---|---|
| recordtype |
dspace |
| spelling |
ir-2011-70022019-05-23T13:25:47Z Oral live attenuated human rotavirus vaccine (RotarixTM) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children JUSTINO, Maria Cleonice Aguiar ARAÚJO, Eliete da Cunha VAN DOORN, Leen-Jan OLIVEIRA, Consuelo Silva de GABBAY, Yvone Benchimol MASCARENHAS, Joana D'Arc Pereira MIRANDA, Yllen Stefania Affonso GUERRA, Sylvia de Fátima dos Santos SILVA, Veronilce Borges da LINHARES, Alexandre da Costa Gastroenterite Rotavírus Eficácia da vacina Belém - PA Pará - Estado Amazônia brasileira In a large Phase III trial conducted in 10 Latin American countries, the safety and efficacy of the live attenuated monovalent rotavirus vaccine RIX4414 was evaluated in 15,183 healthy infants followed up during the first two years of life. Belém was the only site in Brazil included in this multicentre trial. The study in Belém included a subset of 653 infants who were followed up until 24 months of age for protection against severe rotavirus gastroenteritis. These subjects were randomly assigned in a 1:1 ratio to receive two doses of vaccine (n = 328) or two doses of placebo (n = 325) at approximately two and four months of age. Of the 653 enrolled infants, 23 dropped out during the study period. For the combined two-year period, the efficacy of RIX4414 was 72.3% [95% confidence interval (CI) 37.5-89.1%] against severe rotavirus-related gastroenteritis, reaching a protection rate of 81.8% (95% CI 36.4-96.6%) against circulating wild-type G9 rotavirus strains. It is concluded that two doses of RIX4414 are highly efficacious against severe rotavirus gastroenteritis in Belém during the first two years of life and provide high protection against the worldwide emergence and spread of G9P[8] strains. 2015-11-17T13:44:38Z 2015-11-17T13:44:38Z 2012-11 Artigo de Periódico JUSTINO, Maria Cleonice Aguiar et al. Oral live attenuated human rotavirus vaccine (RotarixTM) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children. Memórias do Instituto Oswaldo Cruz, Rio de Janeiro, v. 107, n. 7, p. 846-853, nov. 2012. Disponível em: <http://www.scielo.br/pdf/mioc/v107n7/02.pdf>. Acesso em: 16 nov. 2015. <http://dx.doi.org/10.1590/S0074-02762012000700002>. 0074-0276 http://repositorio.ufpa.br/jspui/handle/2011/7002 eng Acesso Aberto application/pdf |
| institution |
Repositório Institucional - Universidade Federal do Pará |
| collection |
RI-UFPA |
| language |
eng |
| topic |
Gastroenterite Rotavírus Eficácia da vacina Belém - PA Pará - Estado Amazônia brasileira |
| spellingShingle |
Gastroenterite Rotavírus Eficácia da vacina Belém - PA Pará - Estado Amazônia brasileira JUSTINO, Maria Cleonice Aguiar Oral live attenuated human rotavirus vaccine (RotarixTM) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children |
| topic_facet |
Gastroenterite Rotavírus Eficácia da vacina Belém - PA Pará - Estado Amazônia brasileira |
| description |
In a large Phase III trial conducted in 10 Latin American countries, the safety and efficacy of the live attenuated monovalent rotavirus vaccine RIX4414 was evaluated in 15,183 healthy infants followed up during the first two years of life. Belém was the only site in Brazil included in this multicentre trial. The study in Belém included a subset of 653 infants who were followed up until 24 months of age for protection against severe rotavirus gastroenteritis. These subjects were randomly assigned in a 1:1 ratio to receive two doses of vaccine (n = 328) or two doses of placebo (n = 325) at approximately two and four months of age. Of the 653 enrolled infants, 23 dropped out during the study period. For the combined two-year period, the efficacy of RIX4414 was 72.3% [95% confidence interval (CI) 37.5-89.1%] against severe rotavirus-related gastroenteritis, reaching a protection rate of 81.8% (95% CI 36.4-96.6%) against circulating wild-type G9 rotavirus strains. It is concluded that two doses of RIX4414 are highly efficacious against severe rotavirus gastroenteritis in Belém during the first two years of life and provide high protection against the worldwide emergence and spread of G9P[8] strains. |
| format |
Artigo |
| author |
JUSTINO, Maria Cleonice Aguiar |
| author2 |
ARAÚJO, Eliete da Cunha VAN DOORN, Leen-Jan OLIVEIRA, Consuelo Silva de GABBAY, Yvone Benchimol MASCARENHAS, Joana D'Arc Pereira MIRANDA, Yllen Stefania Affonso GUERRA, Sylvia de Fátima dos Santos SILVA, Veronilce Borges da LINHARES, Alexandre da Costa |
| author2Str |
ARAÚJO, Eliete da Cunha VAN DOORN, Leen-Jan OLIVEIRA, Consuelo Silva de GABBAY, Yvone Benchimol MASCARENHAS, Joana D'Arc Pereira MIRANDA, Yllen Stefania Affonso GUERRA, Sylvia de Fátima dos Santos SILVA, Veronilce Borges da LINHARES, Alexandre da Costa |
| title |
Oral live attenuated human rotavirus vaccine (RotarixTM) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children |
| title_short |
Oral live attenuated human rotavirus vaccine (RotarixTM) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children |
| title_full |
Oral live attenuated human rotavirus vaccine (RotarixTM) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children |
| title_fullStr |
Oral live attenuated human rotavirus vaccine (RotarixTM) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children |
| title_full_unstemmed |
Oral live attenuated human rotavirus vaccine (RotarixTM) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children |
| title_sort |
oral live attenuated human rotavirus vaccine (rotarixtm) offers sustained high protection against severe g9p[8] rotavirus gastroenteritis during the first two years of life in brazilian children |
| publishDate |
2015 |
| url |
http://repositorio.ufpa.br/jspui/handle/2011/7002 |
| _version_ |
1832603997089824768 |
| score |
11.755432 |